Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Targeted chemo delivery aims to boost pancreatic cancer surgery success

NCT ID NCT07477418

Disease control Sponsor: University of Vermont Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests whether delivering the chemotherapy drug gemcitabine directly into the artery feeding the tumor can improve surgical outcomes for people with borderline resectable pancreatic cancer. Ten participants will receive standard chemo and radiation, followed by the targeted gemcitabine infusion before surgery. The main goal is to see if this approach is safe and feasible.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Gemcitabine delivered via transarterial microperfusion (RenovoCath catheter)
What this could lead to
If successful, this approach could help more patients with borderline resectable pancreatic cancer have clear surgical margins, potentially improving survival.
What could go wrong
This is a very early, small trial (10 participants) focused on safety and feasibility. The added procedure carries risks like bleeding or infection, and it may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2026

An estimate. Start dates often move.

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed pancreatic ductal adenocarcinoma (PDAC). * Borderline resectable disease as defined by the ABC classification criteria, incorporating one or more of the following: * Anatomy (A): Vascular involvement consistent with borderline resectable or resectable locally advanced-PDAC (e.g., abutment of the superior mesenteric vein or artery, portal vein, or celiac axis) as determined by cross-sectional imaging * Biology (B): Concern for extra-pancreatic metastasis or known N1 disease or suspicious but nonconfirmatory liver/lung lesion(s). CA19-9\>500 after normalized bilirubin * Condition (C): Functional status and comorbidity profile adequate for curative-intent surgery, as assessed by the multidisciplinary team, specifically WHO PS \>/=1. * No prior treatment for PDAC (e.g., chemotherapy, radiation, or surgery). * Age ≥ 18 years. * ECOG performance status of 0 or 1. * Ability to understand and the willingness to sign a written informed consent. Exclusion Criteria: * Locally Advanced PDAC or metastatic PDAC * Histology other than adenocarcinoma * Non-accessible arterial anatomy * Gemcitabine hypersensitivity or contraindication to mFOLFIRINOX therapy based on provider assessment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Borderline resectable pancreatic cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Borderline resectable pancreatic cancer Pancreatic ductal adenocarcinoma (PDAC) Pancreatic neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Vermont Medical Center

    Burlington, Vermont, 05401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.